Edgewise Therapeutics Management
Management criteria checks 3/4
Edgewise Therapeutics' CEO is Kevin Koch, appointed in Aug 2017, has a tenure of 7.75 years. total yearly compensation is $7.60M, comprised of 8.1% salary and 91.9% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $5.31M. The average tenure of the management team and the board of directors is 4.7 years and 5.3 years respectively.
Key information
Kevin Koch
Chief executive officer
US$7.6m
Total compensation
| CEO salary percentage | 8.14% |
| CEO tenure | 7.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 4.7yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Here's Why We're Not At All Concerned With Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
Mar 12
Edgewise Therapeutics: More Expensive Now, But Much More Derisked
Mar 10Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data
Dec 31Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
Nov 26Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)
Sep 19We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Aug 12Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
Aug 05Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run
May 10We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
May 10Edgewise Therapeutics: Behind The Massive Rally
Feb 18Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Dec 07Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Aug 16Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Apr 28We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Jan 13Edgewise Therapeutics proposes $100M stock offering plan
Sep 13Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02
Aug 04Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Aug 02We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Mar 24We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Nov 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$146m |
| Dec 31 2024 | US$8m | US$619k | -US$134m |
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$116m |
| Mar 31 2024 | n/a | n/a | -US$106m |
| Dec 31 2023 | US$4m | US$595k | -US$100m |
| Sep 30 2023 | n/a | n/a | -US$89m |
| Jun 30 2023 | n/a | n/a | -US$81m |
| Mar 31 2023 | n/a | n/a | -US$76m |
| Dec 31 2022 | US$5m | US$572k | -US$68m |
| Sep 30 2022 | n/a | n/a | -US$61m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$5m | US$525k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$36m |
| Jun 30 2021 | n/a | n/a | -US$27m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$2m | US$425k | -US$17m |
| Dec 31 2019 | US$741k | US$425k | -US$10m |
Compensation vs Market: Kevin's total compensation ($USD7.60M) is about average for companies of similar size in the US market ($USD6.15M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
CEO
Kevin Koch (64 yo)
7.8yrs
Tenure
US$7,601,200
Compensation
Dr. Kevin Koch, Ph.D. is a Venture Partner at OrbiMed Advisors, LLC since 2016. He had been a Member of Scientific Advisory Board at OnKure Therapeutics, Inc. until December 2024. Dr. Koch serves as a Memb...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.8yrs | US$7.60m | 0.34% $ 5.3m | |
| Chief Operating Officer | less than a year | US$2.90m | 0.019% $ 300.9k | |
| Chief Medical Officer | 4.1yrs | US$2.92m | 0.021% $ 319.1k | |
| Co-Founder | 7.9yrs | US$2.46m | 0.018% $ 273.8k | |
| Chief Financial Officer | 4.7yrs | US$772.02k | 0.077% $ 1.2m | |
| General Counsel | 4.7yrs | no data | 0.0062% $ 96.6k | |
| Chief Development Officer | less than a year | no data | no data |
4.7yrs
Average Tenure
63yo
Average Age
Experienced Management: EWTX's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.9yrs | US$7.60m | 0.34% $ 5.3m | |
| Co-Founder | 7.8yrs | US$2.46m | 0.018% $ 273.8k | |
| Independent Director | 5.8yrs | US$298.82k | 0.015% $ 230.9k | |
| Independent Director | 4.4yrs | US$307.32k | 0% $ 0 | |
| Independent Director | 1yr | US$781.82k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Independent Chairman | 8yrs | US$326.89k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.2yrs | US$291.32k | 0.010% $ 160.5k | |
| Co-Founder & Independent Director | 4.3yrs | US$295.97k | 0.019% $ 292.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | 5.3yrs | no data | no data |
5.3yrs
Average Tenure
64yo
Average Age
Experienced Board: EWTX's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/17 03:24 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Edgewise Therapeutics, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cory Kasimov | Evercore ISI |
| Paul Choi | Goldman Sachs |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |